Connie is a Principal on the life sciences team at F-Prime based in San Francisco. She focuses primarily on biotechnology investments and also works closely with the Eight Roads Ventures China team to manage F-Prime’s existing and new investment efforts in China. Connie joined F-Prime in 2019, and has been involved in a number of company formation efforts including K36 Tx, Skyline, Pediatrix, and AlphaGen. Prior to joining F-Prime, Connie was a Consultant with IQVIA in New York, where she advised biopharmaceutical companies on commercial, development, and portfolio strategy topics.
Connie holds an M.B.A from Harvard Business School, M.S. from the Harvard Department of Stem Cell and Regenerative Biology, and a B.S.E. in Bioengineering from the University of Pennsylvania.
Martin is Principal based in the Cambridge office. Martin’s primary area of interest is in biotechnology investments in a range of therapeutic areas including oncology, cardiovascular, renal and metabolic diseases. Martin joined F-Prime’s London office in 2019, where he has worked on several biotechnology company creation efforts and investments in Europe, including ARTBIO, CHARM Therapeutics and Tenpoint Therapeutics.
Prior to joining F-Prime, he was a Wellcome Trust Sir Henry Wellcome Postdoctoral Fellow at the MRC Laboratory of Molecular Biology in Cambridge, where he researched molecular mechanisms of DNA replication. Martin completed his PhD at the Cancer Research UK London Research Institute, prior to its incorporation into the Francis Crick Institute, investigating DNA repair by homologous recombination. His research has been published in several original articles in journals such as Cell, Nature and Molecular Cell. Martin also holds BA and MSci degrees in Biochemistry from the University of Cambridge.
Carlos Bustamante joined F-Prime in January 2019 as a Venture Partner based in the San Francisco office, and is focused on the application of data science and genomics technology to problems in medicine, agriculture, and biology. He is currently on leave from Stanford University where he is a Professor of Biomedical Data Science, Genetics, and (by courtesy) Biology, was founding Director of the Stanford Center for Computational, Evolutionary, and Human Genomics and is Inaugural Chair of the Department of Biomedical Data Science.
Carlos has a passion for building new academic units, non-profits, and companies to solve pressing scientific challenges. He is currently a Director at EdenRoc Sciences, LLC and Etalon DX, founder of Arc Bio, LLC and CDB Consulting LTD., and has served as an SAB member for more than a dozen companies.
Carlos received his PhD in Biology and MS in Statistics from Harvard University.
Rosy Howell joined the F-Prime team in March 2017. She is Executive Assistant to Alex Pasteur and Nihal Sinha. Previously, she worked at Henry Milner & Co. as Office Manager and Executive Assistant to Henry Milner. Rosy received her BA in Philosophy and English from the University of Southampton.
Josh is a cofounder of Stavvy, a Boston-based fintech company, where he leads product, engineering, people, and finance. A lifelong technologist, Josh has focused on entrepreneurship, financial services, cybersecurity, privacy, and anti-fraud technology. Josh has been responsible for building and leading teams — from niche startups to large federal agencies — tackling some of the world’s largest fraud, abuse, and security challenges. Before Stavvy, he served as the Chief Security Officer (CSO) at DigitalOcean where he oversaw the legal operations, trust & safety, security, and fraud & abuse teams. Josh also launched Rapid7’s security organization, operating as the CSO he functioned as one of the corporate spokespeople and a member of the product leadership team. In addition to his operational background, Josh continues to serve as a professional advisor at the Martin Trust Center for MIT Entrepreneurship.
Josh earned his Bachelor’s degree from the University of Maryland and his MBA from the Sloan School of Management at MIT.
Matthew Boersma is the Associate Director of FBRI where he works to enable innovative research and therapeutic development for neurodegenerative diseases and related disorders. He engages with multiple stakeholders to facilitate collaborations and information exchange to accelerate the pace of discovery. As part of this role, Matthew also collaborates closely with the F-Prime team and he previously worked with Alzforum to identify and develop new information resources for the neurodegeneration research community. Before joining FBRI, he was a postdoctoral research fellow at Boston Children’s Hospital and Harvard Medical School.
Matthew received a PhD in neuroscience from the Johns Hopkins University School of Medicine and earned an A.B. in neuroscience from Bowdoin College.
Mihir Shah is a veteran technology leader with over 30 years of experience in financial services and technology. He recently retired from Fidelity Investments, where he held several key leadership roles, including Chief Technology Officer (CTO), CIO – Enterprise Head of Data & Analytics, and Head of Enterprise Architecture. His core area of expertise is developing and executing on large, complex data and platform initiatives.
As CTO, Mihir led the modernization of Fidelity’s Asset Management platform, which now enables $5.6 trillion in assets under management. As Chief Data Officer (CDO), he spearheaded the development of a firm-wide, cloud-based data warehouse, unifying all data products into a single analytics platform. Earlier in his career, he played a pivotal role in enhancing Fidelity’s customer experience platforms, leading the rollout of CRM, Customer360, and Campaign Management by developing a unified data architecture for customer-facing channels.
Before Fidelity, Mihir led large-scale projects across the UK, Argentina, Singapore, and the US. He was the lead architect at Churchill Insurance in London, a pioneering startup in the UK insurance industry, and began his career at Tata Consultancy Services (TCS), contributing to its early growth.
In his post-retirement career, he is a Venture Partner at F-Prime Capital, Eight Roads Europe and India. He also serves as an Advisor in Residence to EY and is on advisory boards of numerous companies including Snowflake, Writer, Reltio, Skyflow, Promethium and Finbourne. He remains engaged in academia as an Industry Fellow at MIT Sloan School of Management.
Brett Cook is a Partner at F-Prime, where he focuses on investments in healthcare technology and service companies. At F-Prime, Brett has led or participated in investments in Blue Rabbit (acquired by Wedgewood Pharmacy), Iora Health (acquired by One Medical), PatientPing (acquired by Appriss Heath), VitalWare (acquired by Health Catalyst), 1up Health, AppliedVR, BenchSci, Better Life Partners, Bluebird Kids Health, Equip, Expressable, NOCD, Notable, Paradigm Health, Patina, Proximie, Rippl, and Wellbeam, among others. While at F-Prime, and in collaboration with GV and the Broad Institute, Brett also helped launch and run Project Beacon, a social benefit organization that facilitated more than 1.5 million COVID tests for the Commonwealth of Massachusetts and K-12 schools.
Prior to rejoining F-Prime in 2018, Brett led the finance team at PatientPing (acquired by Appriss Health), a healthcare technology company providing real-time admission and discharge notifications to coordinate patient care. Previously, Brett worked at Aledade and McKinsey & Company.
Brett holds an M.B.A. from Harvard Business School and a B.S.E. in Biomedical Engineering from Duke University.
Derrick Williams is the Receptionist at F-Prime, joining in October 2018. Prior to joining F-Prime, Derrick worked in the Security field with Northeast Security for five years. Derrick attended Gibbs College, where he majored in Computer Networking Operations.
Brian joined F-Prime in 2018 and focuses primarily on investments in the biopharmaceutical and medical technology sectors. Prior to joining F-Prime, Brian was an engagement manager at McKinsey and Company, where he advised pharmaceutical and medical technology companies on business development, R&D, and strategy topics.
Brian holds a PhD in immunology from Yale University and received his B.S. in biochemistry from the University of Notre Dame.